China+1 strategy gains momentum in pharma, but full monetisation still 2-3 years away: Goldman Sachs

Indian pharmaceutical and biotech sectors are experiencing early benefits from the global shift away from China, driven by the China+1 strategy. Companies are seeing increased conversion of inquiries into pilot projects and small contracts, particularly from large pharmaceutical firms seeking supply chain diversification.